5 Best Peptides for Burns

What to Know Before Choosing a Peptide for Burns

Burn injuries are complicated at the biological level. Damaged tissue loses its blood supply, skin cells struggle to migrate across the wound bed, inflammation runs hot, and the collagen that fills in behind healing skin can organize into stiff, raised scar tissue rather than the flexible weave of healthy skin. Peptides enter this conversation as signaling molecules, compounds that can theoretically activate specific repair pathways that standard burn care, including sterile dressings, antibiotics, and surgical debridement, does not directly address. That framing matters because it sets realistic expectations: the peptides discussed here are experimental adjuncts, not replacements for medical treatment.

Every compound in this guide earned its place because people use it for burns or are actively discussing using it for burns. That is the only test for inclusion. A peptide does not need FDA approval, a randomized controlled trial, or even published human data to belong here. What matters is whether it is genuinely part of the conversation. FDA-approved compounds, research chemicals used in community protocols, and a pipeline compound accessible only through clinical trials are all represented below, because all of them reflect what people in the field are actually reaching for. The evidence for each is stated honestly inside its own entry, from compounds backed by multiple research fronts to compounds whose support is almost entirely experiential.

The entries are numbered, but the numbers are a spine for the list, not a verdict. The order reflects how prominently each compound appears in the research and in real-world use for burns, not a recommendation that one compound is better than another for you. BPC-157 leads because it is the most discussed compound across the burn and wound healing field. That prominence does not make it the right choice for every reader. Choosing among these compounds is a personalized decision that depends on your injury, your health history, and what you build with the help of a knowledgeable practitioner.

1. BPC-157: For Vascular Repair and Wound Deepening Prevention

BPC-157, short for Body Protection Compound-157, is a synthetic 15-amino-acid peptide derived from a protein found in gastric juice. It is the most consistently mentioned compound across burn and wound healing discussion in 2026, appearing at or near the top of community tier lists for tissue repair. That prominence comes from a specific biological story: burns destroy blood vessels, and BPC-157 appears to rebuild them.

The mechanism centers on VEGF, which stands for Vascular Endothelial Growth Factor. Think of VEGF as the body's signal to dispatch a construction crew after a pipeline breaks. BPC-157 appears to bind to receptors on the cells that line blood vessels, triggering VEGF production and setting off angiogenesis, the formation of new capillaries. For a burn wound, where oxygen-starved zones form because the original blood supply has been destroyed, restoring that vascular network is a foundational step. Without new vessels, oxygen and nutrients cannot reach damaged tissue to support further repair.

The animal data is genuinely impressive. In rodent burn models, BPC-157 has been associated with roughly a 24 percent reduction in wound area compared to controls, and re-epithelialization, the process by which new skin grows back across the wound bed, reached approximately 78 percent in peptide-treated animals versus 54 percent in controls. The compound also shows anti-inflammatory activity, which matters for preventing secondary tissue damage that can deepen a burn beyond its initial injury zone.

What does not yet exist is a published human clinical trial for burns specifically. There is no randomized controlled trial, no Phase 2 or Phase 3 data, and no FDA approval for any wound indication. Some sources reference Phase 2 trials as pending or upcoming, but no results have been published as of 2026. BPC-157 is sold as a research chemical, labeled for laboratory use only. WADA lists it as a prohibited substance. The gap between its preclinical story and its human evidence base is real, and any honest account has to name it clearly. Community users who report using it for burn recovery are working from that preclinical base and their own experiential accounts, not from a clinical trial.

2. TB-500: For Early Skin Cell Migration

TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring protein involved in cell movement and tissue repair. Where BPC-157 focuses on rebuilding the blood supply, TB-500 addresses a different early problem: getting skin cells to physically move across the wound bed.

Closing a burn wound requires keratinocytes, the cells that make up the outer layer of skin, to migrate from the wound edges toward the center and cover the exposed tissue. That migration depends partly on actin, a structural protein that acts like the internal scaffolding cells use to generate movement. TB-500 regulates actin polymerization, the process by which actin assembles into functional filaments, and it upregulates laminin-332, a structural protein in the extracellular matrix that acts as an anchor and guide rail for migrating cells. The result, in animal models, is faster keratinocyte migration and faster wound closure.

The preclinical data for connective tissue repair is strong, and the re-epithelialization improvements seen in combination studies suggest TB-500 and BPC-157 may work on complementary phases of healing: TB-500 accelerating early skin closure while BPC-157 drives the vascular rebuilding that follows. Community protocols frequently pair them for this reason. For burns specifically, what exists on the human side is a handful of case series and no published randomized controlled trials. Many people who use TB-500 in community protocols report faster recovery from injuries broadly, though a meaningful portion also report no noticeable effect, which aligns with the limited human evidence base.

Like BPC-157, TB-500 is sold as a research chemical, labeled for laboratory use only, and is prohibited by WADA. It cannot be legally prescribed via telemedicine for burn treatment. One practical note that comes up consistently in community discussion: burning or pain at the injection site when using TB-500 is generally considered a sign of poor quality, contamination, or improper reconstitution, not a normal feature of the compound itself.

3. GHK-Cu: For Scar Prevention and Collagen Organization

GHK-Cu is a copper peptide tripeptide, three amino acids bound to a copper ion. It has a longer history of study than most compounds in this field, with wound-healing research going back decades and some randomized controlled trial data in the broader wound healing context. For burns specifically, its primary use case is the scar prevention phase of healing rather than the acute wound-closure phase, which sets it apart from the two compounds above.

The mechanism is more specific than it might seem. Burns trigger a protein called TGF-beta, Transforming Growth Factor Beta, a powerful signaling molecule that activates fibroblasts, the cells responsible for laying down collagen. Overactive TGF-beta leads fibroblasts to deposit collagen in a disorganized pattern, producing the thick, rigid scar tissue that is a frequent long-term consequence of serious burns. GHK-Cu counters this by upregulating decorin, a proteoglycan that acts as a natural regulator of TGF-beta activity. Decorin binds to excess TGF-beta and neutralizes it, which allows fibroblasts to organize collagen in the normal interlocking basket-weave structure rather than the scar-producing parallel bundles.

In practical terms, GHK-Cu is most relevant in the later phase of burn healing, after the acute wound is closing, when collagen organization becomes the primary issue. Community use reflects this: people reach for it both as an injectable research compound and in topical serums, where it appears in commercially available cosmetic formulations. There is an active thread in skincare communities showing before-and-after use of a copper peptide serum on a healing burn, with users reporting accelerated wound closure. These are anecdotal accounts, not clinical outcomes, but they reflect a pattern of real-world use that extends well beyond the injectable research-compound community.

One experience worth flagging: topical GHK-Cu formulations frequently cause a brief burning or stinging sensation upon application. Community discussion and product reviews consistently note this is considered normal and typically resolves within about an hour. It is not a sign of a product problem. Injectable GHK-Cu, like the other injectables in this list, is available as a research chemical and is not FDA-approved for burn treatment.

4. KPV: For Acute Inflammation in the First 24 Hours

KPV is a tripeptide derived from the alpha-melanocyte stimulating hormone sequence, and it is the most timing-sensitive compound in this group. Its primary relevance to burn healing is in the very earliest phase, the first 24 hours after injury, when uncontrolled inflammation causes secondary damage that can deepen the burn beyond its initial zone.

When a burn occurs, the body's inflammatory response sends immune cells, primarily neutrophils and macrophages, to the injury site. These cells release cytokines, inflammatory signaling proteins that include IL-6 and TNF-alpha, which are useful in controlled amounts but destructive when they run unchecked. KPV interrupts this cascade by inhibiting NF-kappa-B, a master transcription factor that functions like a volume dial for the inflammatory response. Lower NF-kappa-B activity, and the downstream cytokine output drops.

The practical consequence for burn care is a shorter, less intense inflammatory phase, which may prevent the zone of stasis, tissue at the edge of a burn that is damaged but not yet dead, from progressing into full necrosis. That is a meaningful potential benefit in the hours immediately after a serious burn, and it is precisely why the timing window is considered critical. Users and practitioners who include KPV in burn protocols emphasize that it needs to be introduced within that first 24-hour window to have meaningful impact. After it passes, the biology moves into later repair stages where KPV's specific contribution diminishes.

The evidence for KPV in burns is preclinical. In vitro and animal model data support the mechanism, but no human clinical trial data has been published for this use as of 2026. What exists is a well-reasoned mechanistic rationale and preclinical confirmation. KPV is available as a research compound, primarily in topical formulations, and is not FDA-approved.

5. NMT-cP12: The Clinical Pipeline Compound

NMT-cP12 is a fibronectin-derived peptide developed by NeoMatrix Therapeutics, and it represents something qualitatively different from every other compound in this list: it is the most advanced burn-specific peptide in human clinical development as of 2026. It has received FDA Orphan Drug Designation and Fast Track Designation for severe burns, and it is the only compound here with published Phase 1 human safety data tied specifically to burn applications.

The mechanism addresses a problem that sits upstream of wound closure. After a serious burn, small blood vessels in and around the injury zone become blocked by aggregates of red blood cells. This occlusion cuts off oxygen delivery to the peri-burn tissue, the area surrounding the burn that is still alive but at risk of dying. NMT-cP12 works by binding to integrin-beta-3 and the transferrin receptor on microvascular cells, and it works synergistically with PDGF-BB, a growth factor, to dilate the microvasculature and reduce that blockage. Improved oxygenation of peri-burn tissue limits how deep and wide the burn ultimately becomes, a form of injury containment rather than wound closure.

The Phase 1 trial enrolled 40 healthy adults and established that NMT-cP12 was safe and well-tolerated at doses up to eight times the anticipated optimal dose, with no serious adverse events. Mild itching and hives appeared at the highest doses only. Published results came out in 2020. A Phase 2a trial, funded by the Department of Defense, was approved and targeting six burn patients with burns covering up to five percent of total body surface area at MedStar Washington Hospital Center. Porcine models also showed reduced scarring and limited injury progression, adding preclinical depth behind the human safety data.

The critical practical note: NMT-cP12 is not available as a research chemical, is not prescribed by any clinic, and cannot be obtained outside of a clinical trial. It belongs in this guide because it genuinely represents where the evidence for burn-targeted peptides is heading, and for people with serious burns or a professional interest in the field, tracking its trial progress is worthwhile. It is not currently an option for self-directed use.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for burn treatment?

No peptide in this guide is FDA-approved for burn treatment in the United States. BPC-157, TB-500, and KPV are sold as research chemicals labeled for laboratory use only. GHK-Cu is available in cosmetic topical formulations but is not approved as a burn therapy. NMT-cP12 has FDA Orphan Drug and Fast Track Designations, meaning the agency has recognized the unmet need and expedited its review pathway, but it remains investigational and is only accessible through clinical trials. The only peptide approved anywhere specifically for burns is FGF-2 (trafermin), which is approved in Japan but not in the United States.

Can these peptides be prescribed through a doctor or telemedicine?

For the research chemicals in this group, BPC-157, TB-500, and KPV, the answer is no, not legally for this use. Unapproved compounds cannot be prescribed via telemedicine for burn treatment under current FDA regulations. GHK-Cu topical formulations are available over the counter in cosmetic products. NMT-cP12 requires clinical trial enrollment. If you are considering any peptide approach alongside burn treatment, working with a physician who is familiar with the evidence base and can evaluate your specific situation is the appropriate path.

Why do some peptides burn during injection, and is that a sign they are working?

Burning during injection of research peptides like BPC-157 or TB-500 is not a sign that the compound is working. It is generally treated as a quality signal, and not a favorable one. Experienced users consistently report that properly prepared, correctly reconstituted peptides should not produce significant pain or burning at the injection site. The most common causes are benzyl alcohol preservatives in multi-dose vials, pH variations in compounded formulations, contamination, or improper reconstitution. GHK-Cu is the exception worth noting: topical copper peptide formulations frequently cause a brief stinging sensation even when the product is authentic and properly made, and this typically resolves within about an hour.

How long before these compounds show results for burns?

No standardized human timeline exists for any of these compounds in burns, because human clinical trial data for most of them is absent or very limited. Animal studies suggest measurable changes in wound area and re-epithelialization over a period of days to weeks. Community users who report results describe them across a similarly wide range depending on burn severity, the compound used, and individual variation. Anyone working with these compounds should understand they are operating from a preclinical evidence base and community-reported experience, not established clinical guidance.

What does the burn peptide pipeline look like going forward?

The most advanced compound in active clinical development is NMT-cP12, which has completed Phase 1 safety testing in 40 adults and has a Department of Defense-funded Phase 2a efficacy trial approved and targeting burn patients. Carocell Bio received ethics approval for ex vivo human preclinical work on its own proprietary peptide candidates in collaboration with Oxford researchers in 2022. Antimicrobial peptides, which address burn wound infection rather than tissue healing directly, have reached Phase 2 and Phase 3 trials for related indications. The pipeline is active and moving, but no therapeutic peptide for burns has cleared Phase 3 or received FDA approval as of 2026.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for burns in one place.